LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), being held in Orlando, Florida from May 29 to June 2. Clinical results from 14 company and investigator-sponsored studies will be reported, including an ongoing study evaluating three dosing regimens of nab®-paclitaxel in combination with targeted agent bevacizumab for first-line treatment of metastatic breast cancer.
